KAHR is developing an innovative and novel drug platform of immunotherapeutic bi-functional fusion proteins that harness the human immune system to target multiple cancer indications.
The Company's lead asset is a first-in-class CD47x41BB targeting compound, activating both innate and adaptive immunity with potential to fight solid tumors.
KAHR’s technology platform is based on multi-functional immuno-recruitment proteins (MIRP) that utilize overexpression of checkpoint antigens on cancer cells to selectively target and bind to the tumor. MIRPs bridge cancer cells to immune cells to produce a targeted synergistic effect by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response, while recruiting the adaptive immune system to bind and selectively kill the cancer cells.
Location: Israel, Jerusalem District, Jerusalem
Total raised: $46.5M
Investors 3
| Date | Name | Website |
| - | aMoon Fund | amoon.fund... |
| 03.08.2023 | Shavit Cap... | shavitcapi... |
| - | Flerie Inv... | flerie.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.06.2021 | - | $46.5M | - |
Mentions in press and media 6
| Date | Title | Description | Source |
| 17.11.2022 | Myeloma Investment Fund Invests in KAHR to Explore Potential... | MODI'IN, Israel, and NORWALK, Conn., Nov. 17, 2022 /PRNewswire/ -- KAHR, a clinical-stage biotech co... | einpresswi... |
| 16.06.2021 | KAHR Announces $46.5 Million Financing to Advance its Multif... | - | amoon.fund... |
| 02.06.2021 | Samsung Biologics and KAHR Medical Announce Development and ... | INCHEON, South Korea, June 2, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's l... | en.prnasia... |
| 25.02.2020 | Kahr raises $18M to test CD47 drug with Roche's Tecentriq | Kahr Medical has raised $18 million (€17 million) to take an anti-CD47 drug into the clinic. The mon... | fiercebiot... |
| 25.02.2020 | Kahr raises $18M to test CD47 drug with Roche's Tecentriq | Kahr Medical has raised $18 million (€17 million) to take an anti-CD47 drug into the clinic. The mon... | fiercebiot... |
| - | KAHR medical | “KAHR develops innovative immuno-recruitment cancer drugs that activate immune responses by converti... | fastfounde... |